| 59 |
decreased |
learning
(GO:0007612)
|
|
341: Impairment, Learning and memory
|
| 60 |
abnormal |
dendrite morphogenesis
(GO:0048813)
|
dendrite
(GO:0030425)
|
382: Aberrant, Dendritic morphology
|
| 62 |
decreased |
synapse assembly
(GO:0007416)
|
synapse
(GO:0045202)
|
385: Decrease of synaptogenesis
|
| 98 |
arrested |
developmental process
(GO:0032502)
|
male reproductive organ
(UBERON:0003135)
|
240: Feminisation or incomplete development, Primary and accessory male sex organs
|
| 99 |
decreased |
regulation of gene expression
(GO:0010468)
|
androgen receptor
(PR:000004191)
|
286: Altered, Transcription of genes by the androgen receptor
|
| 101 |
increased |
aryl hydrocarbon receptor activity
(GO:0004874)
|
aryl hydrocarbon receptor
(PR:000003858)
|
18: Activation, AhR
|
| 159 |
decreased |
Decreased liver function
(HP:0001410)
|
|
164: Induction, Liver “Dysfunctional” Changes by CGA 330050
|
| 105 |
morphological change |
abnormal cardiovascular system physiology
(MP:0001544)
|
|
317: Altered, Cardiovascular development/function
|
| 106 |
increased |
gene expression
(GO:0010467)
|
prostaglandin G/H synthase 2
(PR:000013428)
|
1269: Increase, COX-2 expression
|
| 107 |
increased |
androgen receptor activity
(GO:0004882)
|
androgen receptor
(PR:000004191)
|
25: Agonism, Androgen receptor
|
| 108 |
decreased |
gene expression
(GO:0010467)
|
vitellogenins
(MESH:D014819)
|
285: Reduction, Vitellogenin synthesis in liver
|
| 110 |
decreased |
|
vitellogenins
(MESH:D014819)
|
221: Reduction, Plasma vitellogenin concentrations
|
| 111 |
decreased |
receptor-mediated endocytosis
(GO:0006898)
|
vitellogenins
(MESH:D014819)
|
309: Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
|
| 112 |
decreased |
oocyte growth
(GO:0001555)
|
|
309: Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
|
| 113 |
decreased |
oocyte development
(GO:0048599)
|
|
309: Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development
|
| 115 |
decreased |
|
Follicle stimulating hormone
(CHEBI:81569)
|
129: Reduction, Gonadotropins, circulating concentrations
|
| 116 |
decreased |
calcium-transporting ATPase activity
(GO:0005388)
|
calcium ion-transporting ATPase complex
(GO:0090534)
|
51: Inhibition, Ca++ ATPase
|
| 117 |
increased |
|
calcium ion
(CHEBI:39124)
|
50: Increase, Ca++ (intracellular)
|
| 118 |
disrupted |
|
mitochondrial respiratory chain
(GO:0005746)
|
178: Mitochondrial electron transport chain, disrupted
|
| 120 |
increased |
reactive oxygen species biosynthetic process
(GO:1903409)
|
reactive oxygen species
(CHEBI:26523)
|
1115: Increase, Reactive oxygen species
|
| 121 |
decreased |
|
nitric oxide
(CHEBI:16480)
|
193: Decreased, Nitric Oxide
|
| 122 |
decreased |
long-term synaptic potentiation
(GO:0060291)
|
|
166: Decreased, Long-term potentiation (LTP)
|
| 124 |
decreased |
transport
(GO:0006810)
|
bile salt export pump
(PR:000003549)
|
41: Inhibition, Bile Salt Export Pump (ABCB11)
|
| 125 |
increased |
gene expression
(GO:0010467)
|
bile acid receptor
(PR:000011396)
|
288: Activation of specific nuclear receptors, Transcriptional change
|
| 126 |
increased |
|
bile
(UBERON:0001970)
|
214: Bile accumulation, Pathological condition
|